PITTSBURGH and GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) — Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on extending human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition (“XAGE”, the “Company”, “we”, “our”, or “us”), today announced the following business updates:
1. Merger Agreement entered with 20/20 BioLabs (“20/20”)
-
Merger Agreement executed on April 11, 2025, pursuant to which 20/20 is expected to continue as a wholly owned subsidiary of XAGE following merger closing subject to the satisfaction of the conditions set forth in the Merger Agreement.
-
S-4 prospectus filed with the Securities and Exchange Commission (SEC) on May 8, 2025.
2. Unaudited Q1 sales
-
XAGE: approximately $663,000 on a full quarter pro forma basis, an increase of 8% over the same period last year.
-
20/20: approximately $562,000, an increase of 15% over the same period last year.
3. Reverse Stock Split
-
Completed a 1 for 30 reverse stock split of XAGE’s common stock on May 12, 2025.
-
Stock began trading at split adjusted price on May 14, 2025.
4. Expected Q2 New Product Launches
-
XAGE: expects to launch a medicated cleanser for use in Physicians’ offices and MedSpas. This cleanser will also be marketed to 20/20’s customer base which consists predominantly of firefighters.
-
20/20: expects to launch a new lab test that measures inflammatory biomarkers in the blood, a key contributor to premature aging and precursor to various skin and health disorders. This test will also be marketed to XAGE’s customer base of physicians and MedSpas.
-
20/20: announced an initiative with Giant Food at 9 stores in Maryland and Virginia to offer OneTestTM, their multi-cancer test using capillary blood. Giant is also considering expanding the pilot to include a test that spots biomarkers linked to pro-inflammatory foods.
5. Additional Financing
About 20/20:
20/20 develops and commercializes innovative laboratory tests for the early detection and the proactive management of chronic disease risk. It offers a multi-cancer early detection blood test available in the U.S. accessible at home or at retail locations. This quarter, 20/20 also expects to introduce a new blood test for monitoring chronic inflammation which contributes to eight of the ten leading causes of death in America as well as skin disorders.